Glioblastoma Multiforme (GBM) Therapy Market
The development of new therapies for the Glioblastoma Multiforme is a slow and incremental process. The rate of successfully achieving the primary endpoints quite low for the investigational medications for GBM. Despite challenges, some of the key pharma players are actively engaged in the therapeutics development for Glioblastoma Multiforme such as VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, Oncoceutics, Karyopharm Therapeutics, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Immunomic Therapeutics, Ziopharm, Kintara Therapeutics, Inovio Pharmaceuticals, and several others.
As per the DelveInsight, the overall Glioblastoma Multiforme market size in the seven major markets (i.e the US, Germany, Italy, France, the United Kingdom, Spain, and Japan), following the launch of the expected therapies, is likely to reach 1,083 million by 2023.
For more detailed information, visit: Glioblastoma Multiforme (GBM) Therapy Market